德曲妥珠单抗-话题@MedSci

#德曲妥珠单抗#

4篇内容 | 3208人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2299700, encodeId=64112299e0076, content=<a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a> <a href='/topic/show?id=4c9e136654cf' target=_blank style='color:#2F92EE;'>#HER2 阳性实体瘤#</a> <a href='/topic/show?id=d347136655b2' target=_blank style='color:#2F92EE;'>#FBXL2 蛋白#</a>, objectTitle=四川大学最新Nature Cancer论文：靶向抑制FBXL2，提高T-DXd抗癌效果, objectType=article, longId=925042, objectId=7f5c92504291, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20260127/290dec65548c4ce2bae34a54846f4cef-czJFsGjfrPsb.jpg, objectUrl=/article/show_article.do?id=7f5c92504291, replyNumber=0, likeNumber=4, createdTime=2026-02-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=安徽省, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2290594, encodeId=09b62290594be, content=<a href='/topic/show?id=608c13359e8b' target=_blank style='color:#2F92EE;'>#黏液性卵巢癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=黏液性卵巢癌中HER2突变谱分析，德曲妥珠单抗或可作为潜在治疗方案, objectType=article, longId=908803, objectId=84fe9088039a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240619/1718791326617_5579292.jpg, objectUrl=/article/show_article.do?id=84fe9088039a, replyNumber=0, likeNumber=56, createdTime=2025-11-25, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=84fe9088039a, moduleTitle=黏液性卵巢癌中HER2突变谱分析，德曲妥珠单抗或可作为潜在治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84fe9088039a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2288173, encodeId=67ec22881e302, content=<a href='/topic/show?id=2d88854209c' target=_blank style='color:#2F92EE;'>#腮腺癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=德曲妥珠单抗打破“标准治疗用尽”困境，多线经治HER2扩增型腮腺癌获益六线治疗长达13个月, objectType=article, longId=906341, objectId=fbd090634103, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240707/1720362208683_5579292.jpg, objectUrl=/article/show_article.do?id=fbd090634103, replyNumber=0, likeNumber=51, createdTime=2025-11-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fbd090634103, moduleTitle=德曲妥珠单抗打破“标准治疗用尽”困境，多线经治HER2扩增型腮腺癌获益六线治疗长达13个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbd090634103)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2287977, encodeId=497c228e97752, content=<a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a> <a href='/topic/show?id=258b13134993' target=_blank style='color:#2F92EE;'>#宫颈黏膜黑色素瘤#</a>, objectTitle=德曲妥珠单抗联合特瑞普利单抗成功治疗HER2扩增/点突变的宫颈黏膜黑色素瘤，实现显著缓解, objectType=article, longId=906179, objectId=5fce9061e945, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220801/1659342224826_8252897.webp, objectUrl=/article/show_article.do?id=5fce9061e945, replyNumber=0, likeNumber=62, createdTime=2025-11-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5fce9061e945, moduleTitle=德曲妥珠单抗联合特瑞普利单抗成功治疗HER2扩增/点突变的宫颈黏膜黑色素瘤，实现显著缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fce9061e945)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2287582, encodeId=1c8f228e58270, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=继发肝脏内脏危象的HER2低表达乳腺癌获益德曲妥珠单抗，持续缓解达一年半, objectType=article, longId=905932, objectId=9b419059324f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250219/1739952514024_8538692.jpg, objectUrl=/article/show_article.do?id=9b419059324f, replyNumber=0, likeNumber=68, createdTime=2025-11-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9b419059324f, moduleTitle=继发肝脏内脏危象的HER2低表达乳腺癌获益德曲妥珠单抗，持续缓解达一年半, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b419059324f)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2287575, encodeId=259f228e57502, content=<a href='/topic/show?id=e37c83513be' target=_blank style='color:#2F92EE;'>#胆管癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=胆管癌根治术后复发，检出HER2扩增获益德曲妥珠单抗，再次进展后获益德曲妥珠单抗联合仑伐替尼, objectType=article, longId=905833, objectId=51879058335b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220906/1662451499353_5552845.jpg, objectUrl=/article/show_article.do?id=51879058335b, replyNumber=0, likeNumber=46, createdTime=2025-11-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=51879058335b, moduleTitle=胆管癌根治术后复发，检出HER2扩增获益德曲妥珠单抗，再次进展后获益德曲妥珠单抗联合仑伐替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51879058335b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2287028, encodeId=9977228e028cf, content=<a href='/topic/show?id=e3818e1893' target=_blank style='color:#2F92EE;'>#HER2#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=HER2 IHC阴性别失望，NGS检测来帮忙！HER2基因变异也可指导妇科肿瘤获益德曲妥珠单抗, objectType=article, longId=905303, objectId=b45490530334, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240521/1716265095898_5579292.png, objectUrl=/article/show_article.do?id=b45490530334, replyNumber=0, likeNumber=43, createdTime=2025-10-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b45490530334, moduleTitle=HER2 IHC阴性别失望，NGS检测来帮忙！HER2基因变异也可指导妇科肿瘤获益德曲妥珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b45490530334)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2286819, encodeId=47b22286819f2, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=读书报告 |DESTINY-Gastric 04研究：德曲妥珠单抗对比雷莫卢单抗联合紫杉醇后线治疗晚期胃癌的III期临床研究, objectType=article, longId=903046, objectId=b0a5903046f9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/prescription-form-with-medical-stethoscope-9ZRKVHM.jpg, objectUrl=/article/show_article.do?id=b0a5903046f9, replyNumber=0, likeNumber=55, createdTime=2025-10-30, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b0a5903046f9, moduleTitle=读书报告 |DESTINY-Gastric 04研究：德曲妥珠单抗对比雷莫卢单抗联合紫杉醇后线治疗晚期胃癌的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0a5903046f9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2285494, encodeId=b705228549432, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=真实案例：HER2非19/20外显子突变的转移性非小细胞肺癌也能获益德曲妥珠单抗治疗, objectType=article, longId=903290, objectId=b78190329007, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240618/1718704490473_92910.png, objectUrl=/article/show_article.do?id=b78190329007, replyNumber=0, likeNumber=45, createdTime=2025-10-20, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b78190329007, moduleTitle=真实案例：HER2非19/20外显子突变的转移性非小细胞肺癌也能获益德曲妥珠单抗治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b78190329007)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2284698, encodeId=793c228469881, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=MDT病例分享 | 33岁女性，初诊即晚期：HER2阳性乳腺癌伴广泛转移的诊疗挑战, objectType=article, longId=901973, objectId=dc019019e396, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-examining-medical-report-PJUYHWX.jpg, objectUrl=/article/show_article.do?id=dc019019e396, replyNumber=0, likeNumber=74, createdTime=2025-10-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=dc019019e396, moduleTitle=MDT病例分享 | 33岁女性，初诊即晚期：HER2阳性乳腺癌伴广泛转移的诊疗挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc019019e396)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2268820, encodeId=f23b2268820d7, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=NEJM：总生存期达14.7个月！这类胃癌或迎来新二线治疗策略, objectType=article, longId=881679, objectId=382a8816e9a8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250610/1749532698935_8538692.jpg, objectUrl=/article/show_article.do?id=382a8816e9a8, replyNumber=0, likeNumber=73, createdTime=2025-06-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=382a8816e9a8, moduleTitle=NEJM：总生存期达14.7个月！这类胃癌或迎来新二线治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=382a8816e9a8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2264276, encodeId=70aa22642e647, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=HR阳性HER2扩增转移性乳腺癌接受德曲妥珠单抗治疗后复发，获益奈拉替尼三联方案, objectType=article, longId=875329, objectId=060c8e532934, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-in-his-practice-with-a-digital-tablet-UWZKVBN.jpg, objectUrl=/article/show_article.do?id=060c8e532934, replyNumber=0, likeNumber=85, createdTime=2025-05-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=060c8e532934, moduleTitle=HR阳性HER2扩增转移性乳腺癌接受德曲妥珠单抗治疗后复发，获益奈拉替尼三联方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=060c8e532934)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2252058, encodeId=db0e2252058cd, content=<a href='/topic/show?id=3ae89e29658' target=_blank style='color:#2F92EE;'>#间质性肺病#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=【专家述评】| 德曲妥珠单抗所致间质性肺病全程管理策略, objectType=article, longId=860936, objectId=1c33860936fe, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679867316202_4754896.png, objectUrl=/article/show_article.do?id=1c33860936fe, replyNumber=0, likeNumber=96, createdTime=2025-02-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=1c33860936fe, moduleTitle=【专家述评】| 德曲妥珠单抗所致间质性肺病全程管理策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c33860936fe)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2246443, encodeId=4656224644378, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=绘真约大咖 | 陈晓教授：聚焦HER2阳性肺癌患者，德曲妥珠单抗会带来哪些获益？, objectType=article, longId=857946, objectId=355f85e946df, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/hospital-staff-doctor-review-PTX6YZP.jpg, objectUrl=/article/show_article.do?id=355f85e946df, replyNumber=0, likeNumber=0, createdTime=2025-01-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=355f85e946df, moduleTitle=绘真约大咖 | 陈晓教授：聚焦HER2阳性肺癌患者，德曲妥珠单抗会带来哪些获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=355f85e946df)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2234673, encodeId=0c7422346e3e0, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=绘真约大咖 | 董茜教授：解答胃癌HER2状态检测的一些问题, objectType=article, longId=849439, objectId=743e849439c7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240705/1720150214732_5579292.png, objectUrl=/article/show_article.do?id=743e849439c7, replyNumber=0, likeNumber=111, createdTime=2024-11-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=743e849439c7, moduleTitle=绘真约大咖 | 董茜教授：解答胃癌HER2状态检测的一些问题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=743e849439c7)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2234243, encodeId=50762234243cb, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=德曲妥珠单抗在美国获得上市申请的优先审评资格，用于治疗既往接受过至少一线内分泌治疗的HER2低表达或超低表达转移性乳腺癌, objectType=article, longId=849039, objectId=1c1b849039b9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240919/1726724580886_8538692.png, objectUrl=/article/show_article.do?id=1c1b849039b9, replyNumber=0, likeNumber=119, createdTime=2024-10-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=1c1b849039b9, moduleTitle=德曲妥珠单抗在美国获得上市申请的优先审评资格，用于治疗既往接受过至少一线内分泌治疗的HER2低表达或超低表达转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c1b849039b9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2230710, encodeId=d1cf2230e103f, content=<a href='/topic/show?id=b42f4481873' target=_blank style='color:#2F92EE;'>#妇科肿瘤#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=绘真约大咖 | 李晓玲教授：德曲妥珠单抗获批泛实体瘤，HER2需常规检测！, objectType=article, longId=846823, objectId=3a6184682384, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202401012/1728724318089_8538692.jpg, objectUrl=/article/show_article.do?id=3a6184682384, replyNumber=0, likeNumber=149, createdTime=2024-10-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3a6184682384, moduleTitle=绘真约大咖 | 李晓玲教授：德曲妥珠单抗获批泛实体瘤，HER2需常规检测！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a6184682384)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2222047, encodeId=8857222204e8f, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=JCO：德曲妥珠单抗对多种HER2阳性癌症的客观缓解率高达56.5%！, objectType=article, longId=840328, objectId=e66084032853, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240821/8acc9ccc13514502ace5aca81176618a-kmqU1nl4qRmG.jpg, objectUrl=/article/show_article.do?id=e66084032853, replyNumber=0, likeNumber=138, createdTime=2024-08-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=e66084032853, moduleTitle=JCO：德曲妥珠单抗对多种HER2阳性癌症的客观缓解率高达56.5%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e66084032853)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2221213, encodeId=f5b822212132e, content=<a href='/topic/show?id=13db460162d' target=_blank style='color:#2F92EE;'>#实体瘤#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=JCO：重磅ADC对13种癌症有效，疾病控制率达90.3%！, objectType=article, longId=839493, objectId=4e4a8394932d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240703/1719979466467_5579292.png, objectUrl=/article/show_article.do?id=4e4a8394932d, replyNumber=0, likeNumber=125, createdTime=2024-08-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4e4a8394932d, moduleTitle=JCO：重磅ADC对13种癌症有效，疾病控制率达90.3%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e4a8394932d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2219974, encodeId=832c22199e404, content=<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a> <a href='/topic/show?id=07fe10530819' target=_blank style='color:#2F92EE;'>#德曲妥珠单抗#</a>, objectTitle=中国胃癌患者迎来新一代ADC药物，德曲妥珠单抗治疗 HER2 阳性晚期胃癌在华获批，泛肿瘤治疗更进一步！ , objectType=article, longId=838317, objectId=cee983831e0d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240807/1723003230910_8538692.png, objectUrl=/article/show_article.do?id=cee983831e0d, replyNumber=0, likeNumber=117, createdTime=2024-08-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cee983831e0d, moduleTitle=中国胃癌患者迎来新一代ADC药物，德曲妥珠单抗治疗 HER2 阳性晚期胃癌在华获批，泛肿瘤治疗更进一步！ , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cee983831e0d)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 侠胆医心

阿斯利康和第一三共联合开发和商业化的优赫得®（英文商品名：Enhertu® ，通用名：注射用德曲妥珠单抗）已获得中国国家药品监督管理局正式批准，本品单药适用于治疗既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者。

2023-02-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#德曲妥珠单抗# #HER2 阳性实体瘤# #FBXL2 蛋白#

2026-02-04发表于安徽省

梅斯管理员 (审核中...)

前往app查看评论内容

#黏液性卵巢癌# #德曲妥珠单抗#

黏液性卵巢癌中HER2突变谱分析，德曲妥珠单抗或可作为潜在治疗方案

2025-11-25发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#腮腺癌# #德曲妥珠单抗#

德曲妥珠单抗打破“标准治疗用尽”困境，多线经治HER2扩增型腮腺癌获益六线治疗长达13个月

2025-11-08发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#德曲妥珠单抗# #宫颈黏膜黑色素瘤#

德曲妥珠单抗联合特瑞普利单抗成功治疗HER2扩增/点突变的宫颈黏膜黑色素瘤，实现显著缓解

2025-11-07发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #德曲妥珠单抗#

继发肝脏内脏危象的HER2低表达乳腺癌获益德曲妥珠单抗，持续缓解达一年半

2025-11-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胆管癌# #德曲妥珠单抗#

胆管癌根治术后复发，检出HER2扩增获益德曲妥珠单抗，再次进展后获益德曲妥珠单抗联合仑伐替尼

2025-11-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#HER2# #德曲妥珠单抗#

HER2 IHC阴性别失望，NGS检测来帮忙！HER2基因变异也可指导妇科肿瘤获益德曲妥珠单抗

2025-10-31发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #德曲妥珠单抗#

读书报告 |DESTINY-Gastric 04研究：德曲妥珠单抗对比雷莫卢单抗联合紫杉醇后线治疗晚期胃癌的III期临床研究

2025-10-30发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #德曲妥珠单抗#

真实案例：HER2非19/20外显子突变的转移性非小细胞肺癌也能获益德曲妥珠单抗治疗

2025-10-20发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #德曲妥珠单抗#

MDT病例分享 | 33岁女性，初诊即晚期：HER2阳性乳腺癌伴广泛转移的诊疗挑战

2025-10-14发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #德曲妥珠单抗#

NEJM：总生存期达14.7个月！这类胃癌或迎来新二线治疗策略

2025-06-11发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #德曲妥珠单抗#

HR阳性HER2扩增转移性乳腺癌接受德曲妥珠单抗治疗后复发，获益奈拉替尼三联方案

2025-05-09发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#间质性肺病# #德曲妥珠单抗#

【专家述评】| 德曲妥珠单抗所致间质性肺病全程管理策略

2025-02-15发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #德曲妥珠单抗#

绘真约大咖 | 陈晓教授：聚焦HER2阳性肺癌患者，德曲妥珠单抗会带来哪些获益？

2025-01-03发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #德曲妥珠单抗#

绘真约大咖 | 董茜教授：解答胃癌HER2状态检测的一些问题

2024-11-01发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #德曲妥珠单抗#

德曲妥珠单抗在美国获得上市申请的优先审评资格，用于治疗既往接受过至少一线内分泌治疗的HER2低表达或超低表达转移性乳腺癌

2024-10-31发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#妇科肿瘤# #德曲妥珠单抗#

绘真约大咖 | 李晓玲教授：德曲妥珠单抗获批泛实体瘤，HER2需常规检测！

2024-10-13发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#HER2阳性# #德曲妥珠单抗#

JCO：德曲妥珠单抗对多种HER2阳性癌症的客观缓解率高达56.5%！

2024-08-23发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#实体瘤# #德曲妥珠单抗#

JCO：重磅ADC对13种癌症有效，疾病控制率达90.3%！

2024-08-18发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#胃癌# #德曲妥珠单抗#

中国胃癌患者迎来新一代ADC药物，德曲妥珠单抗治疗 HER2 阳性晚期胃癌在华获批，泛肿瘤治疗更进一步！

2024-08-13发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务